KORU Medical Systems filings document a Nasdaq-listed medical technology issuer focused on large-volume subcutaneous infusion products. The disclosures identify its common stock, operating results, earnings-release exhibits, non-GAAP measures such as adjusted EBITDA and adjusted diluted EPS, and the Freedom System product family used in home self-administration and ambulatory infusion settings.
Its SEC record also covers proxy governance, board and stockholder-meeting procedures, officer and compensation arrangements, and material agreements tied to the business. Recent 8-K filings describe credit-facility arrangements and manufacturing and supply agreements for subassemblies, needle sets, and tubing products.
KORU Medical Systems director and major holder reports stock grant. A Form 4 shows an entity associated with Horton Capital receiving a grant or other acquisition of 3,571 shares of KORU Medical common stock at $0.00 per share.
After this grant, Horton Capital Partners Fund, L.P. is reported with 5,069,541 shares held indirectly, while Joseph M. Manko Jr. also reports 782,547 shares held directly. The filing reflects a compensation or award-type acquisition rather than an open-market purchase or sale.
KORU Medical Systems, Inc. entered into Amendment No. 1 to its Amended and Restated Manufacturing and Supply Agreement with Command Medical Products, LLC. Command manufactures and supplies KORU’s subassemblies, needle sets and tubing products under this agreement.
The amendment extends the initial term so the agreement now runs through December 31, 2031, with automatic one-year renewals unless either party gives at least 180 days notice not to renew. It also revises pricing and payment terms, including product pricing, annual price adjustments and pass-through cost savings.
The amendment adds requirements for Command to obtain and qualify a second manufacturing site by December 31, 2027, and gives KORU a new right to terminate if Command misses this requirement and does not cure within 30 days. Command becomes the exclusive manufacturer of a limited set of products, wind-up period provisions are broadened, intellectual property ownership and licenses are clarified, assignment rights are made mutual, and a prior non-competition provision is removed. Other termination rights, including for uncured material breach within 45 days, bankruptcy or insolvency, and force majeure events lasting at least 30 days, remain in place.
KORU Medical Systems, Inc. President and Chief Commercial Officer Adam R. Kalbermatten reported open-market purchases of company common stock. On one date, he bought 7,500 shares at $3.93 per share and 5,000 shares at $3.96 per share, for a total of 12,500 shares acquired directly.
KORU Medical Systems, Inc. reported the results of its 2026 annual shareholder meeting. Shareholders elected all seven director nominees and cast votes on 36,678,784 shares. They approved an amendment to the 2024 Omnibus Equity Incentive Plan to increase available shares and gave advisory approval to executive compensation.
Shareholders also advised holding future say-on-pay votes every one year and ratified Cherry Bekaert LLP as independent registered public accountants for the 2026 fiscal year. Overall, all management proposals received strong support.
KORU Medical Systems, Inc. Chief Technology Officer Eric Schiller purchased Common Stock in the open market. On May 18, 2026, he bought 5,000 shares at an average price of $3.9125 per share. Following this transaction, he directly owns 5,000 shares of KORU Medical Systems common stock.
KORU Medical Systems, Inc. CEO Linda M. Tharby bought additional company stock in the open market. On May 15, 2026, she purchased 1,191 shares of Common Stock at $3.92 per share. After this transaction, she directly owned 620,622 shares of KORU Medical common stock.
KORU Medical Systems Chief Executive Officer Linda M. Tharby reported an open-market purchase of 1,191 shares of the company’s Common Stock on May 15, 2026. After this transaction, she directly owns a total of 620,622 Common Stock shares.
KORU Medical Systems Chief Executive Officer Linda M. Tharby reported routine equity compensation activity. On May 14, she acquired 13,977 shares of common stock through the vesting of restricted stock units, while 7,326 shares were withheld at $3.94 per share to cover tax obligations.
KORU Medical Systems Chief Operating Officer Christopher Pazdan reported routine equity compensation activity. On the vesting of restricted stock units, he acquired 5,327 shares of common stock and 1,470 shares were withheld to satisfy tax obligations at a value of $3.94 per share. Following these transactions, he holds just over 310,000 shares directly.
KORU Medical Systems, Inc. Chief Operating Officer Christopher Pazdan bought 5,000 shares of Common Stock in an open-market purchase at $3.88 per share. Following this transaction, he directly owns 305,131 shares.